Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

Key Takeaways

• Phase 3 trials PERSEUS, IsKia, and GMMG HD7 compare triplet and quadruplet regimens in transplant-eligible multiple myeloma patients.
• CD38 antibodies are being integrated into treatment protocols, showing improved outcomes with quadruplet regimens.
• Enhanced response rates and progression-free survival are observed with the inclusion of CD38 antibodies in upfront treatment.
• Oncologists are adapting treatment strategies based on these pivotal trial findings to optimize patient outcomes.